Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

EZGO vs ACAD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACAD Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

ACAD Overall Winner 6-Pillar Tally: EZGO 1 – 5 ACAD Matrix Metrics: EZGO 1 – 9 ACAD

As of Nov 20, 2026, Acadia Pharmaceuticals Inc. (ACAD) is the stronger overall head-to-head candidate over EZGO Technologies Ltd. (EZGO) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EZGO carries a Unified Composite Score of 31.5/100 (SELL) at $1.84 (N/M Forward P/E, -19.8% operating margin), whereas ACAD carries 44.8/100 (HOLD) at $17.11 (15.8x Forward P/E, 10.2% operating margin).

  • Technical & Structure Timing Caution: EZGO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 71.3); meanwhile ACAD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EZGO vs ACAD
EZGO NASDAQ
EZGO Technologies Ltd. Ordinary Shares
Motorcycles, Bicycles & Parts
$1.84
+10.84% 1D
Market Cap $2.9M
TTM Revenue $20M
Forward P/E N/M
Beta / 30D Vol -76.02β · 664% Vol
Unified Composite Score
31.5 / 100 SELL
Tech 5.0 Fund 30.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (14.5% over 20 days), RSI 71
RSI-14: 71.3 · SMA20: $1.29 · SMA50: $1.03
ACAD NASDAQ Head-to-Head Winner
Acadia Pharmaceuticals Inc.
Pharmaceutical Preparations
$17.11
-2.73% 1D
Market Cap $3.0B
TTM Revenue $1.20B
Forward P/E 15.8x
Beta / 30D Vol 0.15β · 90% Vol
Unified Composite Score
44.8 / 100 HOLD
Tech 38.0 Fund 54.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.6%), weak momentum, RSI 34
RSI-14: 34.2 · SMA20: $19.31 · SMA50: $20.80

6-Pillar Scorecard Institutional Category Breakdown (EZGO 1 – 5 ACAD)

Columns: Metric · EZGO · ACAD
1. Valuation Multiples ACAD
Forward P/E N/M 15.8x
Trailing P/E N/M 8.3x
PEG Ratio N/M N/M
EV / Revenue 0.1x 2.3x
2. Growth & Scale ACAD
Revenue Growth (YoY) -3.1% +22.8%
Earnings Growth (YoY) +77.1% -26.2%
TTM Revenue (USD) $20M $1.20B
Market Cap $2.9M $3.0B
3. Profitability & Quality ACAD
Gross Margin 5.2% 63.9%
Operating Margin -19.8% 10.2%
Net Profit Margin -55.0% 30.1%
Return on Equity (ROE) -22.2% 31.4%
4. Balance Sheet & Cash Flow ACAD
Cash Generation (TTM) -$3.3M EBITDA $181M
Cash Flow Margin -16.5% EBITDA Mgn 15.0%
Net Cash / Leverage $1066.55 Book/Sh · -22.2% ROE $251M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EZGO
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 41.7% (6th %ile)
Put/Call OI Skew N/A 71.82x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat ACAD
OpEx & R&D Intensity 25.0% of Rev ($5.1M) 53.7% of Rev ($646M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Recreational Vehicles Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EZGO (1) vs ACAD (9)
Institutional Metric EZGO ACAD Criterion Row Edge
Market Capitalization
Scale
$2.9M $3.0B Larger Scale ACAD
Trailing P/E Ratio
Valuation
N/M 8.3x Lower Multiple ACAD
Forward P/E Ratio
Valuation
N/M 15.8x Lower Multiple ACAD
Revenue Growth (YoY)
Growth
-3.1% +22.8% Higher Growth ACAD
Operating Margin (TTM)
Profitability
-19.8% 10.2% Higher Margin ACAD
Net Profit Margin
Profitability
-55.0% 30.1% Higher Margin ACAD
Return on Equity (ROE)
Capital Efficiency
-22.2% 31.4% Higher ROE ACAD
52-Week Range Position
Momentum
56% ($0–$3) 8% ($16–$31) Stronger Trend EZGO
Beta / 30D Volatility
Risk Regime
-76.02β · 664% Vol 0.15β · 90% Vol Lower Realized Risk ACAD
Unified Institutional Score
Composite Signal
31.5 / 100 (SELL) 44.8 / 100 (HOLD) Higher Composite ACAD
Trailing 12M Revenue (USD)
Operating Scale
$20M $1.20B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
5.2% 63.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.1x EV/Rev N/M PEG · 2.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$3.3M EBITDA ($1066.55 Book/Sh · -22.2% ROE) $181M ($251M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EZGO +153.0 pp
EZGO: +137.24% · ACAD: -15.76%
3M Horizon EZGO +124.47 pp
EZGO: +82.18% · ACAD: -42.29%
6M Horizon EZGO +32.49 pp
EZGO: +13.58% · ACAD: -18.91%
1Y Horizon EZGO +2085.55 pp
EZGO: +2059.62% · ACAD: -25.93%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EZGO vs ACAD. Trailing 12-month operating profitability (EZGO -19.8% vs ACAD 10.2%) and valuation multiples (EZGO N/M vs ACAD 15.8x Forward P/E) are benchmarked directly in Pillar 4 below.

EZGO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$20M
Gross Margin5.2%
Op. Margin-19.8%
ROE / Fwd P/E-22.2% · N/M
ACAD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.20B
Gross Margin63.9%
Op. Margin10.2%
ROE / Fwd P/E31.4% · 15.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EZGO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EZGO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ACAD BREAKDOWN
62d in phase · OBV DISTRIBUTION
Current IV 41.7%
IV Percentile 6th %ile
Put/Call OI Skew 71.82x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact ACAD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $18.67 · IV 48.0%

ACAD Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($1,867)

Compare $1,867 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 48.0% ATM IV.

PUT-WALL MONTHLY INCOME Liq B

Dec 18 $17 / $16 Bull Put Spread

Sell 3x $17P · Buy 3x $16P · 32d

Net Entry $75 Credit
Max Credit / Yield +$75 (+33.3% RoM)
Max Risk / Buffer -10.3% Cushion ($225 Mgn)
5d Edge & Liquidity 76% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $20 / $17 Bear Put Spread

Buy 1x $20P · Sell 1x $17P · 32d

Net Entry $85 Debit
T+5d @ -5% Drop +$54 (+64%)
Max Risk / Buffer $85 Capped
5d Edge & Liquidity 1.4x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EZGO Moat Profile Cyclical / Execution-Driven Positioning
Recreational Vehicles Operator
Competes within the Recreational Vehicles value chain with $2.9M market capitalization and -19.8% operating margin.
OpEx & R&D Reinvestment 25.0% of Rev ($5.1M)
90D Engineering Disclosures 0 Published
ACAD Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $3.0B market capitalization and 10.2% operating margin.
OpEx & R&D Reinvestment 53.7% of Rev ($646M)
90D Engineering Disclosures 0 Published

Investor FAQ EZGO vs ACAD Key Questions & Quantitative Answers

As of Nov 20, 2026, Acadia Pharmaceuticals Inc. (ACAD) is the stronger overall head-to-head candidate over EZGO Technologies Ltd. (EZGO) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EZGO carries a Unified Composite Score of 31.5/100 (SELL) at $1.84 (N/M Forward P/E, -19.8% operating margin), whereas ACAD carries 44.8/100 (HOLD) at $17.11 (15.8x Forward P/E, 10.2% operating margin). Technical & Structure Timing Caution: EZGO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 71.3); meanwhile ACAD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ACAD leads the Growth & Scale pillar: EZGO posts -3.1% YoY revenue growth and +77.1% YoY earnings growth on $20M TTM revenue (5.2% gross margin, -19.8% operating margin), compared with ACAD at +22.8% YoY revenue growth and -26.2% YoY earnings growth on $1.20B TTM revenue (63.9% gross margin, 10.2% operating margin). On trailing 12-month operating scale, EZGO generates $20M in USD-normalized revenue versus $1.20B for ACAD. In operating R&D and SG&A reinvestment, EZGO deploys 25.0% of Rev ($5.1M) (0 90-day corporate R&D disclosures) versus 53.7% of Rev ($646M) (0 disclosures) for ACAD.

ACAD screens cheaper on headline valuation multiples. EZGO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-16.5% EBITDA margin), whereas ACAD trades at 15.8x Forward P/E, 8.3x Trailing P/E, N/M PEG, and 2.3x EV/Revenue (15.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EZGO (-22.2% ROE) versus ACAD (31.4% ROE) capital efficiency.

In options market volatility and institutional positioning, EZGO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-76.02β · 664% Vol realized risk). By comparison, ACAD carries 41.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 71.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.15β · 90% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.